Scarica l'app Stockscreener
10.08
5.88%
-0.63
Precedente Chiudi:
$10.71
Aprire:
$10.83
Volume 24 ore:
790.59K
Relative Volume:
2.12
Capitalizzazione di mercato:
$425.37M
Reddito:
$82.71M
Utile/perdita netta:
$-102.24M
Rapporto P/E:
-2.7466
EPS:
-3.67
Flusso di cassa netto:
$-76.57M
1 W Prestazione:
-6.41%
1M Prestazione:
-1.08%
6M Prestazione:
-32.21%
1 anno Prestazione:
-43.02%
Intervallo 1D:
$10.07
$10.86
Intervallo di 1 settimana:
$10.07
$11.09
Portata 52W:
$9.78
$20.70
Urogen Pharma Ltd Stock (URGN) Company Profile
Nome
Urogen Pharma Ltd
Settore
Industria
Telefono
972 9 770 7601
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Confronta URGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
10.08 | 425.37M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-19 | Ripresa | Ladenburg Thalmann | Buy |
| 2024-08-22 | Iniziato | Guggenheim | Buy |
| 2023-02-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-27 | Iniziato | Berenberg | Buy |
| 2020-04-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-13 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | National Securities | Neutral |
| 2019-05-30 | Iniziato | JP Morgan | Neutral |
| 2019-05-29 | Iniziato | Goldman | Neutral |
| 2019-01-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-04-04 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-11-15 | Reiterato | Oppenheimer | Outperform |
| 2017-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mostra tutto
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
UroGen acquires IconOVir’s oncolytic virus assets - Yahoo Finance
UroGen Pharma (NASDAQ:URGN) Coverage Initiated at LADENBURG THALM/SH SH - Defense World
UroGen Pharma Ltd. to Host Earnings Call - ACCESS Newswire
UroGen Plots Expansion, Brings In A New Asset - News & Insights
Low-Gade Upper Tract Urothelial Cancer Market on Track for Major - openPR
UroGen Pharma Acquires Oncolytic Virus From IconOVir Bio -February 20, 2025 at 10:58 am EST - Marketscreener.com
UroGen stock in focus after IconOVir deal (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma Expansion Of Oncology Pipeline Portfolio Through Acquisition Of Assets Relating To Oncolytic Virus Icvb-1042 From Iconovir Bio - Marketscreener.com
UroGen acquires oncolytic virus, expands cancer treatment options - Investing.com
UroGen's Major Pipeline Play: Revolutionary Cancer-Fighting Virus Acquisition Reshapes Growth Strategy - StockTitan
Where are the Opportunities in (URGN) - Stock Traders Daily
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts - Defense World
UroGen Pharma’s (URGN) Buy Rating Reaffirmed at D. Boral Capital - Defense World
UroGen Announces Results from Subgroup Analyses of the Pivotal E - WICZ
Breakthrough Bladder Cancer Treatment Achieves 83% Response Rate, FDA Decision Coming 2025 - StockTitan
D. Boral Capital Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
UroGen Pharma (NASDAQ:URGN) Receives Buy Rating from D. Boral Capital - MarketBeat
UroGen Pharma Ltd. Announces Results from A Long-Term Follow-Up Study with JELMYTO for Primary Treatment of Low-Grade, Upper Tract Urothelial Cancer in Adult Patients - Marketscreener.com
JELMYTO shows long-term effectiveness in cancer study By Investing.com - Investing.com Canada
JELMYTO shows long-term effectiveness in cancer study - Investing.com India
Data From A Long-Term Follow-Up Study To The Olympus Trial Published In The Journal Of Urology - Marketscreener.com
Clinical Trial Results: Cancer Drug Maintains Response for Nearly 4 Years, Surpassing Expectations - StockTitan
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet - Simply Wall St
Urogen Pharma's general counsel sells $82,202 in shares - MSN
(URGN) Trading Advice - Stock Traders Daily
Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells 7,379 Shares of Stock - MarketBeat
SG Americas Securities LLC Has $216,000 Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 4,551 Shares - MarketBeat
Insider Selling: UroGen Pharma Ltd. (NASDAQ:URGN) General Counsel Sells $82,202.06 in Stock - Armenian Reporter
UroGen Pharma's chief medical officer sells shares worth $50,698 - MSN
UroGen Pharma's chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Canada
UroGen Pharma’s chief medical officer sells shares worth $50,698 By Investing.com - Investing.com Nigeria
Urogen Pharma's general counsel sells $82,202 in shares By Investing.com - Investing.com South Africa
URGN (UroGen Pharma) Revenue per Share : $2.39 (TTM As of Sep. 2024) - GuruFocus.com
URGNUroGen Pharma Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
URGN (UroGen Pharma) EPS without NRI : $-2.60 (TTM As of Sep. 2024) - GuruFocus.com
UroGen: Upcoming PDUFA, Some Concerns Remain (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma to Present at Upcoming Investor Conferences - The Bakersfield Californian
JPMorgan Chase & Co. Has $864,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
JPMorgan Chase & Co. Grows Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat
UroGen Pharma’s (URGN) Buy Rating Reiterated at D. Boral Capital - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives Consensus Rating of “Buy” from Brokerages - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts - MarketBeat
UroGen Pharma's (URGN) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
JELMYTO shows promise in long-term cancer treatment study By Investing.com - Investing.com Australia
JELMYTO shows promise in long-term cancer treatment study - Investing.com
New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) - Yahoo Finance
D. Boral Capital Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World
Bladder Cancer Clinical and Non-Clinical Studies, Key - openPR
Barclays PLC Increases Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Barclays PLC - MarketBeat
Urogen Pharma Ltd Azioni (URGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Urogen Pharma Ltd Azioni (URGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Smith Jason Drew | General Counsel |
Jan 31 '25 |
Sale |
11.14 |
7,379 |
82,202 |
26,468 |
| Schoenberg Mark | Chief Medical Officer |
Sep 09 '24 |
Sale |
13.08 |
859 |
11,236 |
145,091 |
| Smith Jason Drew | General Counsel |
Sep 09 '24 |
Sale |
13.08 |
1,521 |
19,895 |
25,226 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):